Invitrogen's Q3 Revenues, Profit Spur 10 Percent Stock Surge | GenomeWeb
NEW YORK (GenomeWeb News) - Invitrogen’s share price jumped 10 percent today after the firm released third-quarter results that showed a double-digit increase in revenues and a swing from a loss to a profit.
 
The firm reported after the close of the market yesterday that its third-quarter revenues had spiked up 11 percent to $315 million and that last year’s losses had been turned to a $31 million profit.
 
The stock was up $8.34 at $91.41 in late afternoon trading today.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.